AKBAAkebia Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Akebia Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKBAThis | $198M#7 | — | 7.9x#12 | 0.8x#2 | 47.5%#3 | 92.4%#3 | 9.9%#3 | -21.2%#4 | — | — | -66.3%#3 | — |
| CTNM | $227M#1 | — | 0.9x#6 | — | -100.0%#11 | -41.9%#8 | — | -24.4%#5 | — | — | — | — |
| VNDA | $226M#2 | — | 1.1x#7 | 1.0x#4 | 8.7%#5 | -1066.7%#14 | -70.0%#5 | -110.3%#12 | — | — | — | — |
| SIGA | $220M#3 | — | 1.3x#9 | 2.3x#5 | -31.8%#7 | -60.7%#9 | 25.1%#2 | 14.1%#3 | — | — | -55.4%#2 | 19.6%#1 |
| KROS | $218M#4 | — | 0.8x#5 | 0.9x#3 | 6775.0%#1 | 146.4%#2 | 27.7%#1 | 33.2%#1 | — | — | — | — |
| EVMN | $215M#5 | 1.1x#1 | 0.8x#3 | 16.6x#7 | 85.7%#2 | -3.1%#7 | -623.6%#7 | -24.8%#6 | — | — | — | — |
| NATR | $211M#6 | 12.0x#2 | 1.5x#11 | 0.4x#1 | 5.7%#6 | 153.7%#1 | 5.2%#4 | 14.3%#2 | — | 9#1 | -13.0%#1 | — |
| RNAC | $196M#8 | — | — | 490.5x#9 | -99.0%#10 | -68.3%#10 | -35851.3%#9 | — | — | — | — | — |
| BBOT | $190M#9 | — | 0.6x#1 | — | — | -80.5%#11 | — | -41.5%#7 | — | — | — | — |
| UPB | $186M#10 | — | 0.7x#2 | 65.2x#8 | 20.4%#4 | -128.4%#12 | -5618.8%#8 | -52.9%#8 | — | — | — | — |
| TRDA | $184M#11 | — | 0.8x#4 | 7.2x#6 | -87.9%#9 | -319.0%#13 | -621.1%#6 | -61.6%#9 | — | — | — | — |
| ALXO | $180M#12 | — | 1.3x#8 | — | — | 24.6%#4 | — | -74.7%#10 | -84.4%#1 | — | — | — |
| INO | $175M#13 | — | 40.1x#13 | 2682.1x#10 | -70.0%#8 | 20.6%#5 | -132871.3%#10 | -1944.6%#13 | -243.9%#2 | — | — | — |
| PEPG | $168M#14 | — | 1.4x#10 | — | — | 0.4%#6 | — | -75.0%#11 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice